These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 11761229

  • 1. MuLV packaging systems as models for estimating/measuring retrovirus recombination frequency.
    Patience C, Takeuch Y, Cosset FL, Weiss RA.
    Dev Biol (Basel); 2001; 106():169-79; discussion 253-63. PubMed ID: 11761229
    [Abstract] [Full Text] [Related]

  • 2. Packaging of endogenous retroviral sequences in retroviral vectors produced by murine and human packaging cells.
    Patience C, Takeuchi Y, Cosset FL, Weiss RA.
    J Virol; 1998 Apr; 72(4):2671-6. PubMed ID: 9525584
    [Abstract] [Full Text] [Related]

  • 3. The potential of retroviral vectors to cotransfer human endogenous retroviruses (HERVs) from human packaging cell lines.
    Zeilfelder U, Frank O, Sparacio S, Schön U, Bosch V, Seifarth W, Leib-Mösch C.
    Gene; 2007 Apr 01; 390(1-2):175-9. PubMed ID: 17045761
    [Abstract] [Full Text] [Related]

  • 4. Suspension packaging cell lines for the simplified generation of T-cell receptor encoding retrovirus vector particles.
    Reuss S, Biese P, Cosset FL, Takeuchi Y, Uckert W.
    Gene Ther; 2007 Apr 01; 14(7):595-603. PubMed ID: 17235289
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Specific packaging of spliced retroviral vector transcripts lacking the Psi-region.
    Pambalk K, Hohenadl C, Salmons B, Günzburg WH, Renner M.
    Biochem Biophys Res Commun; 2002 Apr 26; 293(1):239-46. PubMed ID: 12054590
    [Abstract] [Full Text] [Related]

  • 7. Characterization of human endogenous retrovirus type K virus-like particles generated from recombinant baculoviruses.
    Tönjes RR, Boller K, Limbach C, Lugert R, Kurth R.
    Virology; 1997 Jul 07; 233(2):280-91. PubMed ID: 9217052
    [Abstract] [Full Text] [Related]

  • 8. Development of a suspension packaging cell line for production of high titre, serum-resistant murine leukemia virus vectors.
    Pizzato M, Merten OW, Blair ED, Takeuchi Y.
    Gene Ther; 2001 May 07; 8(10):737-45. PubMed ID: 11420637
    [Abstract] [Full Text] [Related]

  • 9. Packaging of heterologous RNAs by a minimal bovine leukemia virus RNA packaging signal into virus particles.
    Jewell NA, Mansky LM.
    Arch Virol; 2005 Jun 07; 150(6):1161-73. PubMed ID: 15703852
    [Abstract] [Full Text] [Related]

  • 10. Targeted gene transfer to lymphocytes using murine leukaemia virus vectors pseudotyped with spleen necrosis virus envelope proteins.
    Engelstädter M, Buchholz CJ, Bobkova M, Steidl S, Merget-Millitzer H, Willemsen RA, Stitz J, Cichutek K.
    Gene Ther; 2001 Aug 07; 8(15):1202-6. PubMed ID: 11509952
    [Abstract] [Full Text] [Related]

  • 11. Intracellular trafficking of Gag and Env proteins and their interactions modulate pseudotyping of retroviruses.
    Sandrin V, Muriaux D, Darlix JL, Cosset FL.
    J Virol; 2004 Jul 07; 78(13):7153-64. PubMed ID: 15194792
    [Abstract] [Full Text] [Related]

  • 12. A packaging cell line generating CD4-specific retroviral vectors for efficient gene transfer into primary human T-helper lymphocytes.
    Thaler S, Schnierle BS.
    Mol Ther; 2001 Sep 07; 4(3):273-9. PubMed ID: 11545619
    [Abstract] [Full Text] [Related]

  • 13. Characterization of an alternative packaging system derived from the cat RD114 retrovirus for gene delivery.
    Ghani K, Cottin S, de Campos-Lima PO, Caron MC, Caruso M.
    J Gene Med; 2009 Aug 07; 11(8):664-9. PubMed ID: 19507185
    [Abstract] [Full Text] [Related]

  • 14. Transmission of endogenous VL30 retrotransposons by helper cells used in gene therapy.
    Chakraborty AK, Zink MA, Hodgson CP.
    Cancer Gene Ther; 1994 Jun 07; 1(2):113-8. PubMed ID: 7621242
    [Abstract] [Full Text] [Related]

  • 15. A murine leukemia virus derived retroviral vector with a rat VL30 packaging psi sequence.
    Torrent C, Wang P, Darlix JL.
    Bone Marrow Transplant; 1992 Jun 07; 9 Suppl 1():143-7. PubMed ID: 1324044
    [Abstract] [Full Text] [Related]

  • 16. Protection of MLV vector particles from human complement.
    Breun S, Salmons B, Günzburg WH, Baumann JG.
    Biochem Biophys Res Commun; 1999 Oct 14; 264(1):1-5. PubMed ID: 10527830
    [Abstract] [Full Text] [Related]

  • 17. Evidence for nonspecific adsorption of targeted retrovirus vector particles to cells.
    Pizzato M, Blair ED, Fling M, Kopf J, Tomassetti A, Weiss RA, Takeuchi Y.
    Gene Ther; 2001 Jul 14; 8(14):1088-96. PubMed ID: 11526456
    [Abstract] [Full Text] [Related]

  • 18. A retroviral packaging cell line for pseudotype vectors based on glioma-infiltrating progenitor cells.
    Fischer YH, Miletic H, Giroglou T, Litwak S, Stenzel W, Neumann H, von Laer D.
    J Gene Med; 2007 May 14; 9(5):335-44. PubMed ID: 17474071
    [Abstract] [Full Text] [Related]

  • 19. High efficiency retroviral vectors that contain no viral coding sequences.
    Yu SS, Kim JM, Kim S.
    Gene Ther; 2000 May 14; 7(9):797-804. PubMed ID: 10822307
    [Abstract] [Full Text] [Related]

  • 20. The envelope glycoprotein of human endogenous retrovirus HERV-W induces cellular resistance to spleen necrosis virus.
    Ponferrada VG, Mauck BS, Wooley DP.
    Arch Virol; 2003 Apr 14; 148(4):659-75. PubMed ID: 12664292
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.